High urgency

SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams

Detected July 30, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA withdraws approval of SpecGx's ANDA for methylphenidate HCl ER tablets (27, 36, 54 mg), effective immediately.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. SpecGx LLC and any entities relying on its ANDA for manufacturing or distribution of these strengths. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate (withdrawal effective upon publication).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA withdrew approval of the ANDA for methylphenidate HCl ER tablets in 27, 36, and 54 mg strengths.

Who it affects

SpecGx LLC and any entities relying on its ANDA for manufacturing or distribution of these strengths.

What you must do

Cease manufacturing and distribution of these products immediately; assess inventory and notify customers.

Deadline

Immediate (withdrawal effective upon publication).

Source: https://www.federalregister.gov/documents/2026/06/18/2026-12236/specgx-llc-withdrawal-of-approval-of-abbreviated-new-drug-application-for-methylphenidate

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)